Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005-2015

dc.contributor.authorCadogan, Cathal A.
dc.contributor.authorRyan, Cristí­n
dc.contributor.authorCahir, Caitriona
dc.contributor.authorBradley, Colin P.
dc.contributor.authorBennett, Kathleen
dc.date.accessioned2018-03-22T09:56:30Z
dc.date.available2018-03-22T09:56:30Z
dc.date.issued2018-02-28
dc.date.updated2018-03-12T10:17:31Z
dc.description.abstractAims: To examine prescribing trends for benzodiazepines and Z-drugs to General Medical Services (GMS) patients in Ireland. Methods: A repeated cross-sectional analysis of the national pharmacy claims database was conducted for GMS patients aged =16 years from 2005-2015. Prescribing rates per 1000 eligible GMS population were calculated with 95% confidence intervals (CIs). Negative binomial regression was used to determine longitudinal trends and compare prescribing rates across years, gender and age groups. Duration of supply and rates of concomitant benzodiazepine and Z-drug prescribing were determined. Age (16-44, 45-64, =65 years) and gender trends were investigated. Results: Benzodiazepine prescribing rates significantly decreased from 225.92/1000 population (95% CI 224.94-226.89) in 2005 to 166.07/1000 population (95% CI 165.38-166.75) in 2015 (p90 days) for either benzodiazepines or Z-drugs. The proportion of those receiving >1 benzodiazepine and/or Z-drug concomitantly increased from 11.9% in 2005 to 15.3% in 2015. Benzodiazepine and Z-drug prescribing rates were highest for older women (=65 years) throughout the study period. Conclusions: Benzodiazepine prescribing to the GMS population in Ireland significantly decreased from 2005 to 2015, and was coupled with significant increases in Z-drug prescribing. The study shows that benzodiazepine and Z-drug prescribing is common in this population, with a third receiving long-term prescriptions. Targeted interventions are needed to reduce potentially inappropriate long-term prescribing and use of these medications in Ireland.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationCadogan, C. A., Ryan, C., Cahir, C., Bradley, C. P. and Bennett, K. (2018) 'Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005-2015', British Journal of Clinical Pharmacology, 84(6), pp. 1354-1363. doi:10.1111/bcp.13570en
dc.identifier.doi10.1111/bcp.13570
dc.identifier.endpage1363
dc.identifier.issn1365-2125
dc.identifier.issn1365-2125
dc.identifier.issued6
dc.identifier.journaltitleBritish Journal of Clinical Pharmacologyen
dc.identifier.startpage1354
dc.identifier.urihttps://hdl.handle.net/10468/5674
dc.identifier.volume84
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc. on behalf of the British Pharmacological Societyen
dc.rights© 2018, John Wiley & Sons Inc. This is the peer reviewed version of the following article: Cadogan, C. A., Ryan, C., Cahir, C., Bradley, C. P. and Bennett, K. (2018) 'Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005-2015', British Journal of Clinical Pharmacology, 84(6), pp. 1354-1363, doi:10.1111/bcp.13570. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en
dc.subjectBenzodiazepinesen
dc.subjectZ-drugsen
dc.subjectPotentially inappropriate prescribingen
dc.subjectPrimary careen
dc.titleBenzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005-2015en
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
5058.pdf
Size:
992.94 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Loading...
Thumbnail Image
Name:
bcp13570-sup-0001-appendices_s1.docx
Size:
108.07 KB
Format:
Microsoft Word XML
Description:
Supporting Information
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description: